May 22, 2015 - International Neuromodulation Society President-Elect Timothy Deer, MD, in an interview on FindaTopDoc radio, described the development and growth of neuromodulation therapy, noting how innovation is a collaborative effort that is allowing a widening number of patients to benefit. (BlogTalkRadio)
May 22, 2015 - Researchers from Caltech and the University of Southern California Keck School of Medicine reported in Science about a clinical trial in which a man paralyzed for more than 10 years was able to intentionally move a robotic arm controlled through two implanted neural arrays on his posterior parietal cortex. (Medical Xpress)
May 21, 2015 - A research scientist writes about the role of oscillations in helping neurons coordinate their communication, and implications for deep brain stimulation therapy. (Forbes)
May 21, 2015 - A poster at the International Headache Congress in Valencia, reports on a survey in which 49 respondents explained their attitude to electroCore’s non-invasive vagus nerve stimulation treatment for migraines. Respondents were allowed to cite more than one reason. The most-cited reason for starting the therapy (67.3%) was resistance to standard migraine therapy. The most-cited reason for continuation (69.5%) was efficacy. After treatment, 46% of attacks were minimized or halted after two hours, and 61% after four hours. (Briefing Wire)
May 18, 2015 - EndoStim announced CE Mark approval and European launch of its second generation system, EndoStim II, to treat gastroesophageal reflux disease (GERD). (PR Newswire)
May 20, 2015 - Axonics Modulation Technologies, Inc. announced that it has been selected to present its technology advancements during the Innovations in Neuromodulation session at the International Neuromodulation Society's 12th World Congress on June 6th in Montreal. The company makes an implantable sacral neuromodulation system to manage chronic intractable urinary and fecal dysfunction. The system has a rechargeable implantable pulse generator designed to be small and long-lasting. (Business Wire)
May 20, 2015 - Stimulation of either motor or sensory vagus nerve bundles can diminish inflammation, according to a paper in the journal Bioelectric Medicine. (Blackbird PR News)
May 20, 2015 - Helius Medical Technologies has completed enrollment for its pilot clinical trial at the Montreal Neurological Institute in which 14 patients with multiple sclerosis will be treated for balance and gait symptoms over the course of 14 weeks, undergoing a physiotherapy protocol combined with noninvasive stimulation of cranial nerves using the Portable Neuromodulation Stimulator (PoNS™). (Business Wire)
May 19, 2015 - Health Canada approved St. Jude Medical's Prodigy™ spinal cord stimulation system with burst technology, the company announced. The first Canadian patient was implanted with the system earlier this month by Ivar Mendez, M.D., Ph.D, FRCSC, FACS at Saskatoon Health Region’s Royal University Hospital. (Market Watch)
May 14, 2015 - For Mother's Day, a woman writes about how her mother regained some function after treating Lyme Disease symptoms through deep brain stimulation. (Curry County Register)
May 14, 2015 - Deakin University reported in the Journal of Neuropsychology http://onlinelibrary.wiley.com/doi/10.1111/jnp.12070/abstract that repetitive transcranial magnetic stimulation sessions helped reduce symptoms of Mal de debarquement syndrome in six out of seven patients. Now the researchers hope to receive funding to expand the clinical trial. (Herald Sun)
May 13, 2015 - Researchers at Washington University in St. Louis have received a three-year, nearly $1.9 million grant from the Defense Advanced Research Projects Agency (DARPA) for a preclinical study to explore stimulating sensory nerves to add a sense of touch to prosthetic hands. (Newswise)
May 14, 2015 - The International Neuromodulation Society issued a news release about the 12th World Congress abstracts that cover device innovation, expanding indications, and evidence of important outcome measures. Scientific Program Chair and President-Elect Dr. Timothy Deer is quoted as saying neuromodulation is viewed as a new treatment paradigm. (Newswise)
May 14, 2015 - A poster presentation at the International Headache Congress in Valencia, Spain reports that vagus nerve stimulation (VNS) inhibits cortical spreading depression (CSD), which is known to be the cause of migraine aura and a trigger for headache. Both invasive and noninvasive VNS were equally effective, and stimulation of less than 30 minutes reduced CSD for more than three hours, more quickly than prophylactic pharmaceutical migraine treatments. (electroCore)
May 14, 2015 - The University of California Davis Health System announced a clinical trial of a deep brain stimulation (DBS) approach that may limit cognitive decline in patients with Parkinson's disease. The approach involves DBS of the subthalamic nucleus (STN) using low-frequency theta stimulation targeting an isolated portion of the STN involved in cognition. The study will involve detailed before-and-after tests of memory, learning and rule use. (Health Canal)
May 14, 2015 - The Magstim Company Ltd. of Wales announced it has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System, a repetitive transcranial magnetic stimulation system, for the treatment of drug resistant Major Depressive Disorder in the United States. (Magstim)
May 11, 2015 - Privately held StimGuard announced the FDA has approved the start of a clinical trial to evaluate a micro-sized device for overactive bladder (OAB) that can be placed completely through a needle. The announcement says the implant is wirelessly powered by an external, "electroceutical" microchip from Stimwave, a company founded by StimGuard's co-founder, which delivers small pulses of energy to electrodes near surrounding nerves. The StimGuard-device clinical trial is due to start in the U.S. in the summer of 2015. (Business Wire)
May 12, 2015 - Autonomic Technologies, Inc. announced it has received a series D round of financing that raised $38 million. The company said it will use the money to expand its marketing in Europe of Pulsante™, its microstimulator to treat severe headaches, and to fund an ongoing clinical study of the device in the U.S. to treat chronic cluster headache. Pulsante™ has received CE mark approval in Europe for treatment of cluster headache. (Military Technologies)
May 11, 2015 - Nevro Corp. said Boston Scientific Corporation has filed two petitions at the U.S. Patent Office for inter partes review of claims that were previously granted to Nevro. A inter partes petition challenges patent claims based on prior art and publication. (CNN Money)
May 11, 2015 - ImThera Medical said the first two patients with obstructive sleep apnea were implanted with its aura6000 system in its U.S. clinical study. ImThera's device has received CE Mark approval in Europe, and is commercially available in some markets outside the U.S. (Mass Device)
May 8, 2015 - A research team including International Neuromodulation Society member Bengt Linderoth, MD, PhD, has published in Science Advances a proof-of-concept demonstration in laboratory mice of an implantable organic electronic device for neuropathic pain treatment. The implantable device releases the inhibitory neurotransmitter GABA (gamma-aminobuyric acid) into the intrathecal space, electrically controlling the release of this positively charged molecule through by applying a current to drive it through an ion-screening electrophoretic gel in the device distribution channel. (IEEE Spectrum)
May 8, 2015 - The FDA has approved the Senza system, Nevro Corp.'s spinal cord stimulation device that relieves trunk or limb pain without paresthesia. The company said in announcing the approval that the FDA is not restricting patients receiving the therapy from operating motor vehicles, that the system has 3T-conditional MRI compatibility, and received "superiority" labeling from the FDA. The FDA based its approval on a clinical study that showed 75% of patients treated had their chronic pain reduced by 50% within three months. Implant site pain and device lead dislocation were among the adverse events reported. (PR Newswire)
May 8, 2015 - International Neuromodulation Society member Christopher Honey, MD, was described as the only neurosurgeon in British Columbia who performs deep brain stimulation (DBS), in an article about a woman with multiple sclerosis whose DBS surgery to control the tremor of multiple sclerosis was documented by the news team. (Global News)
May 7, 2015 - The International Neuromodulation Society announced two preconferences of the 12th World Congress, an Innovation Day and a daylong set of talks on Mechanisms of Action, on June 6 and 7 respectively -- as well as the Canadian Neuromodulation Society's free public lecture on neuromodulation the afternoon of June 6. (Business Wire)
May 7, 2015 - The University of Texas Southwestern Medical Center in Dallas will be one of three sites to offer enrollment in a clinical trial of MicroTransponder Inc.'s vagus nerve stimulation system, Vivistim®, during post-stroke rehabilitation of arm function. (News-Medical.net)
May 6, 2015 - Researchers report a first-in-human, sham-controlled study of transcutaneous electrical vagus nerve stimulation in 40 patients who planned to undergo ablation for atrial fibrillation. After following the patients for several months, they say the results support the emerging paradigm of using neuromodulation to manage drug-refractory atrial fibrillation, which is attract for being nonpharmacological and nonablative. In 20 patients in the treatment arm, the study authors used a metal clip on the right ear to apply low-level stimulation to the auricular branch of the vagus nerve at the tragus. (Cardiac Rhythm News)
May 6, 2015 - A Canadian woman whose multiple sclerosis lead to disabling tremors received a deep brain stimulation implant that will be turned on in June. She said already her symptoms have lessoned now that the electrodes are in place. (Muskokaregion.com)
May 6, 2015 - A paper presented at the American Association of Neurological Surgeons annual meeting, based on a retrospective analysis of 762 patients, appears to support earlier findings that spinal cord stimulation efficacy is inversely proportional to the wait time. (Healio)
May 6, 2015 - Intraoperative monitoring during spinal cord stimulation implantation can help verify accurate placement of the leads, according to a paper presented at the American Association of Neurological Surgeons annual meeting. The prospective study of 73 patients indicated that electromyography in particular may help streamline programming by indicating which contacts may be ideal. (Healio)
May 6, 2015 - An analysis of 350 patients at 36 centers in the St. Jude Medical EMP3OWERTM study indicates that tailoring lead type, number, and targeting of stimulation area improved clinical outcomes and correlated with increased odds of decreased opioid usage, according to a presentation at the American Association of Neurological Surgeons annual meeting. (Healio)
May 6, 2015 - Researchers at Martinos Center for Biomedical Imaging at Massachusetts General Hospital reported using conductive polymers for novel potential neurostimulation leads that, through a similar radio-frequency interaction used to cloak some stealth aircraft, break up induced current, leading to less heating under magnetic resonance imaging conditions, according to tests with standard gel-filled models. They say the resistive tapered stripline technology reduces MRI-induced heating and allows use of higher-Tesla imaging systems. (The Engineer)
May 4, 2015 - St. Jude Medical announced it has completed acquisition of Spinal Modulation, Inc. The acquisition was completed on May 1. Spinal Modulation developed the Axium™ spinal cord stimulation system. That system has approval in the European Union and Australia. Results of a U.S. clinical trial, ACCURATE, will be presented at the International Neuromodulation Society 12th World Congress in June in Montreal, according to the company's announcement. (Business Wire)
May 4, 2015 - A young man who has both obsessive compulsive disorder (OCD) and autism was treated for his severe, disabling OCD symptoms with deep brain stimulation (DBS). International Neuromodulation Society member Robert Buchanan, MD, said this case is the first in which a patient with that dual diagnosis has received DBS. He said it seems to help the brain's intrinsic rhythms of electrical activity become more normalized. The patient, who sought treatment two years ago, said he is more focused and interactive as a result. Researchers at Seton Brain and Spine Institute in Austin, Texas hope to focus on on why DBS worked, and whether it can help autism patients live fairly normal lives as well, the news coverage says. (KHOU)
To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.
How Has Neuromodulation Been Developed and Used?
Conventional medicine has typically had four modes of treating diseases or disorders: counseling or “talk therapy”; physical therapy involving manipulation and strengthening of muscles and range of motion; pharmaceuticals that act on a chemical level; and altering or augmenting tissue through surgery, injections, or filtering methods like dialysis. The growing field of neuromodulation is a new class of therapies that involves directly treating the nervous system itself, often through small implanted devices that target a specific area, to rebalance the activity of neural circuits and manage symptoms.
Progress has been spurred by advances in our understanding of the nervous system, as well as new technologies and clinical experience, enabling treatments to modify nerve cell activity in brain, spinal cord and periphery to restore function, minimize pain, and treat disease symptoms. Developed over the last 45 years, neuromodulation has grown rapidly into a family of therapies that applies stimulation or agents directly to the nervous system, often using small implanted medical devices that are powered in a similar fashion to a cardiac pacemaker. By delivering electrical or chemical stimulation, neuromodulation has increasingly been used to treat motor disorders such as Parkinson’s disease, refractory chronic pain ranging from neuropathy to cancer related pain to severe headaches, spasticity, epilepsy, and incontinence. It is also under study for conditions ranging from gastroparesis to medically refractory depression. Providers of such therapies include neurosurgeons, pain physician specialists and rehabilitation physicians. They may often work with other specialists such as neurologists, psychiatrists, psychologists, gastrointestinal or colorectal specialists, urologists, primary care physicians, and physical therapists to achieve best outcomes.
Learn More . . .
Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use Membership Application.
Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Resources and Research pages. Neuromodulator trials address symptom control through nerve stimulation in such condition categories as:
If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.
The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation - the alteration of nerve activity through the delivery of electrical stimulation or chemical agents to targeted sites of the body. Founded in 1989 and based in San Francisco, CA, the INS educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites.
See patient information
Now indexed in MEDLINE!
Neuromodulation: Technology at the Neural Interface contains articles of the highest scientific caliber. The journal's sole purpose is to advance the basic and clinical science of the field of neuromodulation. In eight issues a year, it publishes scientific works, scientific reviews, and abstracts of papers accepted for review at national and international congresses.
Neuromodulation is now indexed in Index Medicus, MEDLINE and Pubmed!
Click here to submit a manuscript.
Unique Member Benefit
Members may log in and visit the members-only section’s Global Discussion Forum to participate;
watch for updates on our
Events page and in our journal
Members may now join: